These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22231749)

  • 21. Eculizumab in paroxysmal nocturnal hemoglobinuria.
    Kathula SK
    N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17192547
    [No Abstract]   [Full Text] [Related]  

  • 22. From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging.
    Risitano AM; Imbriaco M; Marando L; Seneca E; Soscia E; Malcovati L; Iori AP; Pane F; Notaro R; Matarazzo M
    Br J Haematol; 2012 Aug; 158(3):415-8. PubMed ID: 22571809
    [No Abstract]   [Full Text] [Related]  

  • 23. Eculizumab in paroxysmal nocturnal hemoglobinuria.
    Singh J; Malani AK; Pabla M
    N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17195307
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Hill A
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):849-50. PubMed ID: 16491626
    [No Abstract]   [Full Text] [Related]  

  • 26. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria.
    Tomita A; Shirasugi Y; Ito T; Tsurumi H; Naoe T
    Ann Hematol; 2012 Jul; 91(7):1139-41. PubMed ID: 22080148
    [No Abstract]   [Full Text] [Related]  

  • 28. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890
    [No Abstract]   [Full Text] [Related]  

  • 29. Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria.
    Grigg A; Brown M; Szer J
    Intern Med J; 2010 Nov; 40(11):794-5. PubMed ID: 21108715
    [No Abstract]   [Full Text] [Related]  

  • 30. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab.
    Danilov AV; Smith H; Craigo S; Feeney DM; Relias V; Miller KB
    Leuk Res; 2009 Jun; 33(6):e4-5. PubMed ID: 18952283
    [No Abstract]   [Full Text] [Related]  

  • 31. Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure.
    Kelly RJ; Hill A; Arnold LM; Khursigara G; Kanagasundaram NS; Hillmen P
    Leuk Res; 2011 Apr; 35(4):560-2. PubMed ID: 21145109
    [No Abstract]   [Full Text] [Related]  

  • 32. Disseminated gonococcal infection and eculizumab--a "high risk" connection?
    Hublikar S; Maher WE; Bazan JA
    Sex Transm Dis; 2014 Dec; 41(12):747-8. PubMed ID: 25581812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.
    Knoll BM; Letendre L; Steensma DP
    Am J Hematol; 2008 Nov; 83(11):881-3. PubMed ID: 18756538
    [No Abstract]   [Full Text] [Related]  

  • 34. [Novel therapeutics for paroxysmal nocturnal hemoglobinuria].
    Nishimura J
    Rinsho Ketsueki; 2011 Oct; 52(10):1515-24. PubMed ID: 21971228
    [No Abstract]   [Full Text] [Related]  

  • 35. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria.
    Emadi A; Brodsky RA
    Am J Hematol; 2009 Oct; 84(10):699-701. PubMed ID: 19705437
    [No Abstract]   [Full Text] [Related]  

  • 36. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.
    Risitano AM; Notaro R; Luzzatto L; Hill A; Kelly R; Hillmen P
    N Engl J Med; 2010 Dec; 363(23):2270-2. PubMed ID: 21121856
    [No Abstract]   [Full Text] [Related]  

  • 37. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
    Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
    Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy.
    Genthon A; Chiarabini T; Baylac P; Valin N; Urbina T; Pacanowski J; Mekinian A; Brissot E; M 'Hammedi-Bouzina F; Lapusan S; Mohty M; Lacombe K; Ingiliz P
    Leuk Lymphoma; 2021 Jun; 62(6):1502-1505. PubMed ID: 33416421
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiphospholipid antibodies in patients with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
    Darnige L; Peffault de Latour R; Zemori L; Socié G; Fischer AM; Helley D;
    Br J Haematol; 2011 Jun; 153(6):789-91. PubMed ID: 21457219
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
    Dmytrijuk A; Robie-Suh K; Cohen MH; Rieves D; Weiss K; Pazdur R
    Oncologist; 2008 Sep; 13(9):993-1000. PubMed ID: 18784156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.